{"id":971807,"date":"2026-06-13T06:25:03","date_gmt":"2026-06-13T10:25:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/"},"modified":"2026-06-13T06:25:03","modified_gmt":"2026-06-13T10:25:03","slug":"dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/","title":{"rendered":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States"},"content":{"rendered":"

<\/p>\n

Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae<\/sup>, in the United States<\/b><\/p>\n

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE<\/a>)–
\nDr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif\u00ae, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy\u2019s has collaborated with MSN Laboratories Private Limited (\u201cMSN\u201d), a leading pharmaceutical company in India, on this product. Dr. Reddy\u2019s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.<\/p>\n

\nBosutinib Tablets (400mg) was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.<\/p>\n

\nMilan Kalawadia, CEO- North America, Dr. Reddy\u2019s Laboratories, Inc. said: \u201cThis launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.\u201d<\/p>\n

\nBharat Reddy, Executive Director, MSN Laboratories added: \u201cThe successful development and commercialization of Bosutinib Tablets demonstrates MSN\u2019s strong scientific, regulatory, and manufacturing capabilities in complex oncology products. We remain committed to delivering high-quality, affordable medicines globally through efficient development and reliable manufacturing excellence.\u201d<\/p>\n

\nThe Bosulif\u00ae brand (400mg) had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.<\/p>\n

\nBosulif\u00ae is a registered trademark of Wyeth LLC.<\/p>\n

\nRDY-0626-887<\/p>\n

\n\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026<\/p>\n

About Dr. Reddy\u2019s<\/b>: Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of \u2018Good Health Can\u2019t Wait\u2019, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include \u2013 USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com<\/a>.<\/p>\n

About MSN Laboratories: <\/b>MSN Laboratories is a research-driven pharmaceutical company with integrated capabilities across APIs and finished dosage formulations. The company is recognized for its strong expertise in product development, regulatory execution, and world-class manufacturing infrastructure with USFDA approved facilities in Hyderabad, India and in New Jersey, USA. MSN serves global markets with a focus on quality, affordability, and operational excellence across multiple therapeutic segments, including oncology.<\/p>\n

\n\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026<\/p>\n

\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency \/ severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260613138727\/en\/<\/a><\/span><\/p>\n

INVESTOR RELATIONS
\n<\/b>
AISHWARYA SITHARAM
\n
aishwaryasitharam@drreddys.com<\/a><\/span><\/p>\n

MEDIA RELATIONS
\n<\/b>
PRIYA K
\n
PRIYAK@DRREDDYS.COM<\/a><\/p>\n

KEYWORDS:<\/b> New Jersey United States India North America Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif\u00ae, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy\u2019s has collaborated with MSN Laboratories Private Limited (\u201cMSN\u201d), a leading pharmaceutical company in India, on this product. Dr. Reddy\u2019s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing … <\/p>\n

Continue reading “Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-971807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif\u00ae, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy\u2019s has collaborated with MSN Laboratories Private Limited (\u201cMSN\u201d), a leading pharmaceutical company in India, on this product. Dr. Reddy\u2019s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing … Continue reading "Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-13T10:25:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States\",\"datePublished\":\"2026-06-13T10:25:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/\"},\"wordCount\":852,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/\",\"name\":\"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-06-13T10:25:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk","og_description":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif\u00ae, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy\u2019s has collaborated with MSN Laboratories Private Limited (\u201cMSN\u201d), a leading pharmaceutical company in India, on this product. Dr. Reddy\u2019s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing … Continue reading \"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-13T10:25:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States","datePublished":"2026-06-13T10:25:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/"},"wordCount":852,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/","name":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-06-13T10:25:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260613138727r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-announces-the-first-to-market-launch-of-bosutinib-tablets-400mg-a-generic-equivalent-of-bosulif-in-the-united-states\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif\u00ae, in the United States"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=971807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=971807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=971807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=971807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}